Neurology Franchise
Sage is exploring new disease pathways for certain neurologic disorders.
We are focusing on disorders where there is a high unmet need for additional treatment options. Sage is working to understand the underlying mechanisms for numerous disorders of the brain and central nervous system (CNS) to help us develop therapies that may address current treatment gaps for patients. We focus our research and development efforts on modulation of GABA and NMDA receptors, two critical neurotransmitter systems that have responsibility for information flow within the intricate circuits of the brain and central nervous system.
Both GABA and NMDA systems contribute significantly to regulating CNS function. However, dysfunction in these two systems is known to be at the core of numerous neurological disorders. Navigating these complex circuits is a challenge, but a welcome opportunity for the teams at Sage as we seek to provide new treatments for patients.
We are using our unique development approach to systemically evaluate our drug candidates in a range of neurological, neurodegenerative, and neurodevelopment disorders:
